Low Serum Albumin Level Is a Risk Factor for Delayed Methotrexate Elimination in High-Dose Methotrexate Treatment.

Tatsuo KataokaHiroshi SakurashitaKazuya KajikawaYasuyuki SaekiTakanori TaogoshiHiroaki Matsuo

Published in: The Annals of pharmacotherapy (2021)

Our study showed that low ALB is a risk factor for delayed MTX elimination in HD-MTX monotherapy. Pharmacokinetic analysis is needed to establish the dose of HD-MTX in patients with a low ALB level.

Keyphrases

high dose
low dose
stem cell transplantation
combination therapy
randomized controlled trial
clinical trial